Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
64x Bio
AddedFeb 17, 2024
UpdatedJul 1, 2026
64x Bio

64x Bio

Series A

64x Bio accelerates cell & gene therapy with high throughput cell line design for biomanufacturing.

HQ
San Francisco, CA, US
Founded
2017
Accelerator
Y Combinator logoY CombinatorS18
Overview
Compare
Fundraising
Employees
Website

64x Bio, founded with a mission to revolutionize cell and gene therapy, focuses on accelerating the discovery and optimization of mammalian cell lines for biomanufacturing. Their core vision is to transform the future of therapeutics by leveraging a high throughput discovery and screening platform integrated with computational design. This innovative approach aims to generate highly optimized cell lines, particularly for the production of viral vectors used in cell and gene therapies, thereby enhancing the efficiency and scalability of therapeutic manufacturing processes.

Notable figures affiliated with 64x Bio include experts in genome engineering and computational biology, though specific names are not provided. The company has attracted significant interest from investors in the biotech sector due to its groundbreaking technology. Key achievements include the development of their proprietary platform that significantly speeds up cell line discovery and optimization. The overall impact of 64x Bio lies in its potential to drastically improve the production and accessibility of next-generation therapeutics, positioning itself as a pivotal player in the biomanufacturing landscape.

64x Bio - Similar Companies

Synvivia logo

Synvivia

synvivia.com

WhiteLab Genomics logo

WhiteLab Genomics

whitelabgx.com

Xcell Biosciences logo

Xcell Biosciences

xcellbio.com

CellChorus logo

CellChorus

cellchorus.com

Sixfold Bioscience logo

Sixfold Bioscience

sixfold.bio

Culture Biosciences logo

Culture Biosciences

VintaBio logo

VintaBio

vintabio.com

ExpressCells logo

ExpressCells

Arcturus BioCloud logo

Arcturus BioCloud

arcturus.io

Cell BioEngines logo

Cell BioEngines

cellbioengines.com

Scaled Biolabs logo

Scaled Biolabs

scaledbiolabs.com

Rbio logo

Rbio

rbio.online

Sensible Biotechnologies logo

Sensible Biotechnologies

sensible.bio

Nabla Bio logo

Nabla Bio

nabla.bio

Exegenesis Bio logo

Exegenesis Bio

exegenesisbio.com

64x Bio - Quick Facts

Who are 64x Bio's competitors?

Companies similar to 64x Bio include Synvivia, WhiteLab Genomics, Xcell Biosciences and CellChorus.

When was 64x Bio founded?

64x Bio was founded in 2017.

Where is 64x Bio's headquarters located?

64x Bio's headquarters is located in San Francisco, CA, US.

When was 64x Bio's last funding round?

64x Bio's most recent funding round was for $55M (USD) in January 2022.

How much has 64x Bio raised to-date?

As of Jan 19, 2022, 64x Bio has raised a total of $59.6M (USD).

How many employees does 64x Bio have?

64x Bio has 30 employees as of Feb 4, 2024.

64x Bio - Classification

Ownership
  • Venture Capital
Technology
  • Biotech
Geographic Exposure
  • Global
Model
  • Platform
Revenue
  • Recurring
  • Software
Customer
  • Enterprise
Main Product
  • Cell Line Design
Tags
  • SaaS
NAICS
  • 540000Professional, Scientific, and Technical Services
  • 541500Computer Systems Design and Related Services
  • 541000Professional, Scientific, and Technical Services
  • 541510Computer Systems Design and Related Services
  • 541511Custom Computer Programming Services
SIC
  • 7300Business Services
  • 7370Computer Programming, Data Processing, And Other Computer Related
  • 7371Computer Programming Services
Show 15 more industry codes
NAICS
  • 513200Software Publishers
  • 541714Research and Development in Biotechnology (except Nanobiotechnology)
  • 510000Information
  • 620000Health Care and Social Assistance
  • 513000Publishing Industries
  • 541700Scientific Research and Development Services
  • 513210Software Publishers
  • 541710Research and Development in the Physical, Engineering, and Life Sciences
SIC
  • 8000Health Services
  • 8700Engineering, Accounting, Research, Management, And Related Services
  • 8040Offices And Clinics Of Other Health Practitioners
  • 8730Research, Development, And Testing Services
  • 7372Prepackaged Software
  • 8049Offices And Clinics Of Health Practitioners, Not Elsewhere Classified
  • 8731Commercial Physical and Biological Research